Lykos’ MDMA-Assisted PTSD Therapy Heads to FDA After Adcomm Setback

While an FDA advisory committee voted overwhelmingly against approving the psychedelic therapy, experts suggest it may still have a chance.

On Aug. 11, the FDA is expected to make one of the year’s most highly anticipated decisions: whether or not to approve Lykos Therapeutics’ MDMA-assisted treatment for post-traumatic stress disorder.